Aardvark Therapeutics vs vTv Therapeutics
AARD and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AARD and VTVT compare
vTv Therapeutics is the larger company, worth 2.7 times as much as Aardvark Therapeutics ($77.9M against $29.1M).
vTv Therapeutics scores higher on the StockData Score (11 against 6 for Aardvark Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AARD | VTVT |
|---|---|---|
| Size and price | ||
| Market cap | $29.1M | $77.9M |
| Share price | $1.33 | $19.69 |
| Change, 1 year | −87.6% | −36.5% |
| Change, 5 years | – | −65.3% |
| Beta (5Y) | 2.65 | 1.08 |
| Employees | 40 | 26 |
| StockData Score | ||
| Total score | 6 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.1× |
| P/B | 0.5× (better) | 1.1× |
| Fair value | – | $40.43 |
| Margin of safety | – | 51.3% |
| Growth | ||
| Revenue growth (TTM) | – | 216600% |
| Profitability | ||
| Operating margin | – | −29.8% |
| Net margin | – | −20.8% |
| Return on equity | −80.9% | −11.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.11 | 11.19 (better) |
| Altman Z-score | −4.08 | 0.51 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 43.6% | 40.6% |
| Held by insiders | 41.9% | 26.3% |
| Insider net buying, 12 months | −$250K | – |
| Short interest, % of float | 8.2% | 5.0% |
Go deeper
- AARD stock overview
- AARD income statement
- AARD valuation and score
- VTVT stock overview
- VTVT income statement
- VTVT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.